---
title: "Sanofi-Aventis Deutschland GmbH and others v Amgen, Inc (UPC CoA 528/2024, 25-03-2026)"
description: "The Court of Appeal allowed Sanofi and Regeneron to withdraw their applications for rehearing of its November 2025 decision upholding Amgen's patent EP 3 666…"
url: https://pitch.law/academy/upc-court-of-appeal/upc-coa-528-2024-2026-03-25
lang: en
author: "UPC Case Law by Pitch"
editor: "Bart Lieben"
datePublished: 2026-11-18T10:07:32.765Z
dateModified: 2026-11-18T10:07:32.765Z
---

# Sanofi-Aventis Deutschland GmbH and others v Amgen, Inc

Decision of the UPC Court of Appeal of 25 March 2026, UPC CoA 528/2024.

UPC Case Law by Pitch, edited by [Bart Lieben](https://pitch.law/team/bart-lieben) · Published 18-11-2026

## TL;DR

The Court of Appeal allowed Sanofi and Regeneron to withdraw their applications for rehearing of its November 2025 decision upholding Amgen's patent EP 3 666 797, and declared the proceedings closed. It confirmed that the withdrawal rule in R 265 RoP applies to rehearing applications. It refused any refund of court fees because the applicants had paid only one fee for two rehearing applications when two were due.

## Key holding

R 265.1 RoP, which allows a claimant to withdraw an action as long as there is no final decision, applies equally to appeals and to applications for rehearing under R 245 RoP. Where the other party consents to withdrawal, the Court of Appeal permits it. Although R 265.2(c) RoP provides for a cost decision under R 150-152 RoP, no cost decision is needed where no party requests one. A party that paid only one court fee for two rehearing applications, when two fees were due, has no claim to reimbursement under R 370.9(b) RoP.

## Questions decided

1. Does R 265 RoP on withdrawal apply to applications for rehearing?
2. Is withdrawal of a rehearing application permitted where the other party consents?
3. Must the Court issue a cost decision on withdrawal if no party requests one?
4. Can court fees be reimbursed under R 370.9(b) RoP where only one of two due fees was paid?

## Case details

- Court: Court of Appeal of the Unified Patent Court
- Panel: Klaus Grabinski, President of the Court of Appeal; Nathalie Sabotier, legally qualified judge and judge-rapporteur; Peter Blok, legally qualified judge
- Date: 25-03-2026
- Case number(s): UPC CoA 528/2024, UPC CoA 529/2024
- Parties: Applicants: Sanofi-Aventis Deutschland GmbH, Sanofi-Aventis Groupe S.A., Sanofi Winthrop Industrie S.A. (together "Sanofi") and Regeneron Pharmaceuticals Inc. (respondents before the Court of Appeal, claimants at first instance); Respondent: Amgen, Inc (appellant before the Court of Appeal, defendant at first instance)
- Language of the proceedings: English
- Outcome: The Court of Appeal permitted the withdrawal of the applications for rehearing in UPC CoA 528/2024 and UPC CoA 529/2024 and declared the proceedings closed.

## How to cite

Court of Appeal, Sanofi-Aventis Deutschland GmbH and others v Amgen, Inc, UPC CoA 528/2024, UPC CoA 529/2024, Decision of 25 March 2026 (OSCOLA)

## Full summary

Read the full analyses for free — create a free account: https://pitch.law/academy/upc-court-of-appeal/upc-coa-528-2024-2026-03-25

Topics: [Costs and court fees](https://pitch.law/academy/upc-court-of-appeal/topics/costs-and-fees), [Procedure](https://pitch.law/academy/upc-court-of-appeal/topics/procedure)

## In the same case

- [Amgen, Inc v Sanofi-Aventis Deutschland GmbH and others, UPC CoA 528/2024, 25-11-2025](https://pitch.law/academy/upc-court-of-appeal/upc-coa-528-2024-2025-11-25): The Court of Appeal overturned the Munich central division and upheld Amgen's PCSK9 antibody patent EP 3 666 797 against Sanofi and Regeneron, finding that the skilled person had no reasonable expectation of success that an antibody would be therapeutically effective.

## More on costs and court fees

- [Guardant Health, Inc. v Sophia Genetics SA and others, UPC CoA 49/2026, 05-11-2026](https://pitch.law/academy/upc-court-of-appeal/upc-coa-49-2026-2026-11-05): The Court of Appeal set aside a EUR 600,000 award of representation costs because the successful party had backed it only with invoices reading "supply of legal services" and general assertions about complexity and urgency.
- [Rematec GmbH & Co KG v Europe Forestry B.V., UPC CoA 88/2026, 13-10-2026](https://pitch.law/academy/upc-court-of-appeal/upc-coa-88-2026-2026-10-13): The Court of Appeal refused leave to appeal against a Mannheim Local Division order that rejected two late cost-fixing applications and the related requests for re-establishment of rights.
- [Academy of Military Medical Sciences v Gilead Sciences, Inc., UPC CoA 121/2026, 18-09-2026](https://pitch.law/academy/upc-court-of-appeal/upc-coa-121-2026-2026-09-18): The automatic suspensive effect of an appeal against a revocation decision under Art 74(2) UPCA covers only the ruling on the patent's validity.
- [Dainese S.p.A. v Alpinestars S.p.A. and others, UPC CoA 97/2026, 10-09-2026](https://pitch.law/academy/upc-court-of-appeal/upc-coa-97-2026-2026-09-10): The Court of Appeal held that an appeal lodged within the two-month time limit is not inadmissible merely because the court fee is paid after that limit expires.
- [SharkNinja Operating LLC v Groupe SEB France and others, UPC CoA 61/2026, 21-08-2026](https://pitch.law/academy/upc-court-of-appeal/upc-coa-61-2026-2026-08-21): The Court of Appeal overturned the Paris Local Division and granted SharkNinja a provisional injunction in France and Germany against SEB's "Cookeo Infinity" multicookers.
